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High-mobility group AT-hook 1 (HMGA1) protein is an important nuclear factor that activates gene
transcriptionbybindingtoAT-richsequencesinthepromoterregionofDNA.Wepreviouslydemonstrated
that HMGA1 is a key regulator of the insulin receptor (INSR) gene and individuals with defects in HMGA1
havedecreasedINSRexpressionandincreasedsusceptibilitytotype2diabetesmellitus.Inaddition,thereis
evidence that intracellular regulatory molecules that are employed by the INSR signaling system are
involved in post-translational modifications of HMGA1, including protein phosphorylation. It is known
that phosphorylation of HMGA1 reduces DNA-binding affinity and transcriptional activation. In the
present study, we investigated whether activation of the INSR by insulin affected HMGA1 protein
phosphorylation anditsregulationofgenetranscription.Collectively,ourfindingsindicatethat HMGA1is
anoveldownstreamtargetoftheINSRsignalingpathway,thusrepresentinganewcriticalnuclearmediator
of insulin action and function.
H
MGA1 is a small basic protein that binds to adenine-thymine (A–T) rich regions of DNA and functions
mainly as a dynamic regulator of chromatin structure and gene transcription
1. Although without intrinsic
transcriptional activating activity, HMGA1 acts as an ‘architectural’ transcription factor that can transacti-
vate promoters through mechanisms that facilitate the assembly and stability of a multicomponent enhancer
complex, the so-called enhanceosome, that drives gene transcription in response to multiple extracellular and
intracellular signals
2,3. Such signals may affect HMGA1 function by inducing changes in post-translational protein
modifications (including methylation, acetylation and phosphorylation) thatmarkedly influence HMGA1 ability to
interact with DNA substrates, other proteins and chromatin
2,4–7. DNA-binding activity of HMGA1 is reduced by
HMGA1 phosphorylation, whereas protein dephosphorylation increases HMGA1-DNA binding affinity
8,9,s u gg e s t -
ing a mechanism in which variations in the protein’s biological activity can be specifically produced through
mechanisms of phosphorylation/dephosphorylation of HMGA1, leading to gene repression or activation, respectively.
Previous observations in vitro suggest that changes in HMGA1 protein phosphorylation may occur in a
mechanism involving the intracellular regulatory molecules INSR substrate-1 (IRS-1) and phosphatidylinositol
3-kinase (PI-3K)
10that are critical intermediate steps in transmitting the signal fromthe INSR. On the other hand,
a relationship between HMGA1 and the INSR signaling system has been demonstrated before, showing that
HMGA1 is a key regulator of the expression of the INSR, a major component of the insulin signaling pathway
11,12.
However, the precise role and function of HMGA1 phosphorylation in the INSR signaling system have not yet
been addressed and more empirical evidence is needed to ascertain the biological significance of this HMGA1
post-translational modification and its regulation within this context. Based on our findings in the present work,
we are currently proposing that HMGA1 (specifically the HMGA1a isoform) is a novel downstream target of the
INSRsignalingpathway,whichmayplayanimportantroleintheregulationofinsulinsignalingandactioninvivo.
Results
Activation of IGFBP-1 gene transcription by HMGA1 and its suppression by insulin. Insulin-like growth
factor-binding protein-1 (IGFBP-1) is a major member of the superfamily of IGF binding proteins. Under
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IGFBP-1 seems to be an important determinant in regulating IGF-I
bioavailability and bioactivity
13,14. By binding endogenous IGF-I
during fasting, IGFBP-1 may serve to prevent the hypoglycemic
effects of IGF-I, thus supporting a physiological role for IGFBP-1
in glucose counterregulation
15. Insulin plays a major role in the
regulation of IGFBP-1, rapidly suppressing its production by the
liver at the level of gene transcription
15. Instead, a positive role of
HMGA1 inIGFBP-1 gene expression hasbeen postulated previously
on the basis of experimental evidence showing that HMGA1 binds
the IGFBP-1 gene promoter
16. Consistent with this latter possibility,
we previously found that IGFBP-1 expression was considerably
reduced in Hmga1-knockout mice
17. To investigate whether a
functional link could be established between the INSR signaling
system and HMGA1, we first performed experiments to see if
HMGA1 had a direct role in activating IGFBP-1 gene transcrip-
tion. As shown in reporter gene assays, overexpression of HMGA1
significantly increased IGFBP-1-luciferase (IGFBP-1-Luc) activity
in cells of both human (HepG2) and mouse (Hepa1) origin, and
this effect occurred in a dose-dependent manner (Fig. 1a and Sup-
plementary Fig. S1). Consistent with this, endogenous IGFBP-1
mRNA was reduced in cells pretreated with siRNA targeting
HMGA1 (Fig. 1a and Supplementary Fig. S1), indicating that
activation of the IGFBP-1 gene requires HMGA1. These results
were corroborated by chromatin immunoprecipitation (ChIP)
coupled with qRT-PCR of ChIP-ed samples, showing that binding
of HMGA1 to the endogenous IGFBP-1 chromosomal locus was
increased in living HepG2 cells naturally expressing HMGA1, and
was considerably decreased in cells exposed to siRNA against
HMGA1 (Fig. 1b). A functional link between insulin and HMGA1,
at this level, was substantiated by showing that insulin-mediated
inhibition of IGFBP-1 protein production was abolished in HepG2
cellsmarkedlydepleted ofHMGA1 (Fig. 1c), aswellasin cells treated
with distamycin A (Fig. 1d), a small molecule inhibitor of HMGA1
protein binding to DNA
12.I n s u l i nper se had no effect on HMGA1
protein expression in HepG2 cells (Fig. 1c,d), in which inhibition of
IGFBP-1 protein production byinsulin paralleled closely the decrease
in HMGA1 occupancy at the endogenous IGFBP-1 locus (Fig. 1e,f).
INSRsignalingandHMGA1activity.TherelevanceofHMGA1for
the INSR signaling system was supported in studies in vivo, under
physiological circumstances where endogenous insulin production
can vary (e.g., in response to fed and fasting states). As detected by
ChIP in vivo coupled to qRT-PCR, HMGA1-DNA interaction was
disrupted in liver of insulin-injected mice (Fig. 2a). Similar results
were confirmed in liver from normal mice with augmented insulin
levels as obtained after meal ingestion. As shown in Fig. 2a, binding
of HMGA1 to the IGFBP-1 locus was increased in mice under
physiological fasting conditions when nutrients are limited, insulin
levels are decreased and the insulin signaling cascade (IRS-1/PI-3K/
Akt) is abrogated. Conversely, HMGA1-DNA interaction promptly
decreased after refeeding, when insulin levels increase and insulin
signaling is reactivated (Fig. 2a).
ToprobefurthertheroleofHMGA1inthissignalingpathway,we
examined the effect of wortmannin, a potent and selective inhibitor
of the PI-3K/Akt cascade
18, on HMGA1-mediated stimulation of
IGFBP-1 in liver from insulin treated mice. Systemic treatment with
wortmanninhadnoeffectontheexpressionoftheproteinkinaseAkt
in liver; however, it significantly inhibited the level of insulin-
inducedAktphosphorylation(Fig.2b).Treatmentwithwortmannin
resulted in 50–55% decrease by comparison with immunoblotting
intensity for phosphorylated Akt in liver treated with insulin and
vehicle (Fig. 2b). As measured by ChIP in vivo, on whole liver, and
subsequent qRT-PCR of ChIP-ed samples, as a consequence of
the inactivation of PI-3K/Akt cascade, occupancy of the IGFBP-1
promoter by HMGA1 was increased in wortmannin-treated mice
compared to mice injected with insulin (Fig. 2b). Thus, these data
suggest that HMGA1 can elicit in vivo functional responses that are
acutelyregulatedthroughtheINSRsignalingpathway,whoseactiva-
tion/deactivation state appears to be decisive in the control of
HMGA1-DNA interaction and function. This conclusion was sub-
stantiated by the following additional experimental observations,
which revealed that an inverse correlation between increased IRS-1
phosphorylation and decreased HMGA1 DNA-binding activity
existed in liver from insulin-injected mice, as measured by immuno-
precipitation/westernblot(IP/WB)ofcytoplasmicproteinsandelec-
trophoretic mobility shift assay (EMSA) of liver nuclear extracts,
respectively (Fig. 2c). Accordingly, IGFBP-1 mRNA abundance
wasreducedinliverfrominsulin-treatedanimals,andthisreduction
paralleled the decrease in IGFBP-1 protein levels as detected by IP/
WBfromliverlysates(Fig.2c).Inhibitionofinsulinsignalinginvivo,
using the pharmacological PI-3K inhibitor wortmannin, by increas-
ing HMGA1 DNA-binding, partially reversed the inhibition of
IGFBP-1 mRNA and protein expression by insulin (Fig. 2d), thus
indicating that phosphorylation of HMGA1 represents a fun-
damental step in INSR signaling and that functional regulation of
HMGA1 by phosphorylation/dephosphorylation may be important
during acute (short-term) regulation of glucose homeostasis in res-
ponse to both hormonal and nutritional changes. This conclusion
was supported by studies in primary cultured hepatocytes, showing
that repression by insulin of the gluconeogenic genes phosphoe-
nolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase), as well as the IGFBP-1 gene, was differentially affected in
primarycultured cellsfromnormal wild-typeand Hmga1-null mice.
As shown in Fig. 2e, mRNA expression of PEPCK, G6Pase and
IGFBP-1 was lower in primary hepatocytes from Hmga1-null mice
than in untreated wild-type-derived cells; following insulin treat-
ment, mRNA levels for these genes decreased by 50% in cells from
controlmice,whereasnochangesweredetectedincellsfrommutant
animals, indicating that the regulation of HMGA1, by changing its
phosphorylation, is a critical event mediating the insulin’s effect on
these genes and that insulin action on gluconeogenesis is at least in
part mediated by HMGA1.
Insulin induced post-translational phosphorylation of HMGA1
and its dynamic interaction with DNA. Phosphorylation of
HMGA1 and its relevance for the INSR signaling system was
investigated in detail in studies of post-translational modifications
and nuclear localization of HMGA1 both in vitro and in vivo,
following insulin treatment. As measured by liquid chromato-
graphy-mass spectrometry (LC-MS), a significant early increase of
the tri-phosphorylated HMGA1a isoform protein was detectable in
HepG2 cells at 30 min after insulin addition (Fig. 3a). Specificity of
theinsulin-inducedHMGA1aphosphorylationwassubstantiatedby
theobservationthatHMGN1,anHMGproteinnotinvolvedinINSR
signaling, did not change its phosphorylation state during insulin
treatment (Fig. 3b). Consistently with the assumption that reduced
HMGA1-DNA interaction after meals may reflect the physiological
increase in insulin secretion and insulin signaling, enhanced
HMGA1a phosphorylation was confirmed also in vivo, in liver
from insulin-injected mice (Fig. 3c). As for other chromatin pro-
teins, the apparently small magnitude of insulin-induced HMGA1
protein phosphorylation, both in HepG2 cells and in mouse liver, is
compatible with the activation of a signaling pathway impinging
on selected factors positioned at the level of specific regulatory
sequences. In this regard, phosphorylation of histone H3 at serine
10 or 28 in the induction of immediate-early genes downstream of
theMAPKpathways,constitutesoneofthemoststrikingexamples
19.
As determined by tryptic-peptide mapping of the phosphorylated
protein and the relative extracted ion count (EIC) of the peptides,
di- and tri-phosphorylation of HMGA1 occurred predominantly at
the C-terminal peptide 88-106 (Supplementary Fig. S2), a region
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 251 | DOI: 10.1038/srep00251 2Figure 1 | FunctionalsignificanceofHMGA1forIGFBP-1expression. (a)Left,humanIGFBP-1-Lucreportervector(2mg)wastransfectedintoHepG2
cells, plus increasing amounts (0, 0.5 or 1 mg) of HMGA1 effector plasmid. Total plasmid DNA amounts were normalized with empty vector and Luc
activitywasassayed.Datarepresentthemeans6s.e.m.forthreeseparateexperiments;valuesareexpressedasfactorsbywhichinducedactivityincreased
above the level of Luc activity obtained in transfections with IGFBP-1-Luc reporter vector plus the empty effector vector, which is assigned an arbitrary
value of 1. White bar, pGL3-basic vector (without an insert). Right, inhibition of endogenous IGFBP-1 mRNA in HepG2 cells pretreated with anti-
HMGA1siRNAoranontargetingcontrolsiRNA.WBsofHMGA1ineachconditionareshownintheautoradiograms.b-actin,controlofproteinloading.
*P , 0.05 versus control (black bar); **P , 0.05 versus siRNA-untreated (control) cells. (b) ChIP of the IGFBP-1 promoter gene (and a non-AT-rich
sequence in the IGFBP-1 locus, right side) in HepG2 cells, either untreated or pretreated with HMGA1 siRNA, using an anti-HMGA1 specific antibody
(Ab). Representative assays are shown, together with qRT-PCR of ChIP-ed samples. *P , 0.05 versus control (slashed bar). (c,d) Insulin-mediated
IGFBP-1 suppression inHepG2 cells untreated or pretreated with either HMGA1-siRNA or distamycin A(100–150 mM). Conditioned medium samples
andcellnuclearextractswerecollectedafter12 hinsulintreatmentandassayedbyWBforIGFBP-1andHMGA1,respectively.Densitometerscanningof
IGFBP-1signalsareshowninbargraphs.ResultsareexpressedaspercentagesoftheIGFBP1production inthepresenceofnontargetingsiRNA(control)
or vehicle alone. *P , 0.05 versus untreated cells. (e,f) Representative ChIPs of the IGFBP-1 promoter gene with anti-HMGA1 antibody (Ab) and qRT-
PCR of ChIP-ed samples under the same conditions as in (c,d). *P , 0.05 versus untreated cells (slashed bars).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 251 | DOI: 10.1038/srep00251 3Figure 2 | HMGA1DNA-bindingactivityandfunctionisregulatedbyinsulin. (a)Representative ChIPsofIGFBP-1withanti-HMGA1 antibody (Ab).
Top,fastedmicewereintraperitoneallyinjectedwithinsulin(1 U/kgbw,n512)4 hpriortosacrifice.Bottom,ChIPwasperformedinmiceunderfasted
(n 5 10) and fed (n 5 12) states. qRT-PCR of ChIP-ed samples is shown in each condition. *P , 0.05 versus controls (slashed bars) (b) Akt activity and
HMGA1-DNAbinding.Groupsoffastedmice(n56each)wereinjectedi.v.withorwithoutwortmannin,followedbyinsulininjection.Left,WBoftotal
(Akt) and phosphorylated (pAkt) Akt in liver lysates from untreated and treated mice. Densitometric quantifications of three independent experiments
from six animals per group are shown. b-actin, control. *P , 0.05 versus control vehicle alone; **P , 0.05 versus vehicle plus insulin. Right,
representativeChIPofIGFBP-1withanti-HMGA1antibody (Ab)andqRT-PCRofChIP-edsamplesinliverfromtreatedanduntreated mice.*P,0.05
versus untreated mice (slashed bar). **P , 0.05 versus insulin alone. (c) Left, IP/WB of phosphorylated (pIRS-1) and total IRS-1 in liver from mice
injected or not with insulin, and HMGA1-DNA binding (EMSA) of nuclear extracts from untreated (lanes 1, 2 and 3) and insulin-treated (lane 4) mice.
SupershiftingoftheHMGA1-DNAcomplex(arrowhead)isshownbyusinganti-HMGA1antibody(Ab).Control(unrelatedrabbitserumIgG)antibody
didnotalterthemobilityofthecomplex.Right,liverIGFBP-1mRNAabundancewasanalysedbyqRT-PCRinmice4 hafterintraperitonealinjectionof
insulin or saline. A representative IGFBP-1 immunoblot (IP/WB) of whole-cell liver extracts is shown. b-actin, control. Densitometry of four to six
independentblotsisprovided.*P,0.05versusuntreated(saline)mice.(d)LiverIGFBP-1mRNAandprotein(IP/WB)levelsweremeasuredasin(c),in
insulin-injected mice, in the absence or presence of wortmannin. Densitometry of six independent blots is shown. *P , 0.05 versus untreated (vehicle)
mice.**P,0.05versusinsulinplusvehicle.(e)Insulin-mediated genesuppression inprimarycultured hepatocytes fromwild-type(1/1)andHmga1-
null (2/2) mice. The mRNA levels of PEPCK, G6Pase and IGFBP-1 were measured by qRT-PCR in primary cultured cells untreated or treated with
10 nM insulin for 12 h. Data are shown as the means 6 s.e.m. of five independent experiments. *P , 0.05 versus untreated (1/1) cells. Protein
expression of HMGA1 from primary hepatocytes is shown in WBs. b-actin, control.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 251 | DOI: 10.1038/srep00251 4Figure 3 | Insulin-induced HMGA1 phosphorylation and its intranuclear distribution in living cells. (a–b) HMG proteins (A1a and N1) from untreated
(control) and 30 min insulin-treated HepG2cellswere purified by RP-HPLC andanalysed by massspectra. (c) Massspectra ofliver HMGA1aprotein from
saline (control) and insulin-injected wild-type mice. Livers from five animals were pooled for each determination. Abundances of di- (2P, in green) and tri-
phosphorylated (3P, in orange) HMGA1a isoforms, together with the unmodified (0P, in red) and mono-phosphorylated (1P, in blue) HMGN1 isoforms
areshownasbargraphs.(d)RepresentativeChIPofIGFBP-1withanti-HMGA1antibody(Ab)andqRT-PCRofChIP-edsamplesandendogenousIGFBP-1
mRNA (right side) in HepG2 cells untreated or treated with insulin, in the presence or absence of the protein kinase CK2 inkibitor TBB. *P , 0.05 versus
untreated cells (slashed bars), in each assay; **P , 0.05 versus insulin alone. (e) Expression and function of HMGA1a (wild-type) and its triple
(HMGA1am) and single (HMGA1am-Ser) mutants as indicated on the top of WB, in HEK-293 cells, barely expressing endogenous HMGA1a. Cells were
cotransfectedwithIGFBP-1-Lucreportervector andequalamounts ofeitherHMGA1awild-type(greybars) orHMGA1amutants (slashedbars)expression
plasmid. At 48 h after transfection, cells were incubated in the absence (2) or presence (1) of insulin and cell lysates were prepared 4 h later. Cell lysates
were divided into two aliquots; one of these aliquots was used for Luc activity, and the other was used for WB analysis as a control of HMGA1 protein
expression.Lucactivityineachconditionisexpressedasapercentageofthereporteractivityobtainedintransfectionswiththewild-type(HMGA1a) effector
vector, in the absence of insulin. White bars, mock (no DNA); black bars, pcDNA3 vector without an insert. Data represent the means 6 s.e.m. for three
separate experiments.Representative WBs of endogenousand overexpressed HMGA1a andHMGA1a mutantproteins are shown. *P , 0.05versus insulin-
untreated control (HMGA1a) cells. (f) Time lapse imaging of intranuclear distribution of GFP-HMGA1a in living HepG2 cells, after treatment (0, 15 and
30 min) with either insulin (10 nM) or wortmannin (100 nM), alone, or a combination of both. Intranuclear distribution of the triple mutant GFP-
HMGA1am, in the presence of insulin, is shown. Pictures are optical sections made with a confocal laser scanning microscope. Bars correspond to 2 mm.
www.nature.com/scientificreports
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10,20. Constitutive and
inducible phosphorylation at this level involves the serine residues
Ser98, Ser101 and Ser102 and it has been demonstrated to be
dependent on PI-3K via a casein kinase 2 (CK2)-like specificity
10,21.
Whether detachment of HMGA1 from DNA is due to a direct or
indirect mechanism, our data demonstrate that phosphorylation of
the C-terminal tail is linked to this event. This view was supported
by experiments performed with the highly specific CK2 inhibitor
4,5,6,7-tetrabromo-1H-benzimidazole (TBB), showing that both
detachment of HMGA1 from DNA and inhibition of endogenous
IGFBP-1mRNAbyinsulin wereprevented byinhibitingCK2kinase
activity (Fig. 3d), while the cyclin-dependent kinase inhibitor
alsterpaullone and the protein kinase C (PKC) inhibitor Go ¨6976
had no effects on these functions (Supplementary Fig. S3). The
role of the multiple serine residues Ser98-Ser101-Ser102 on insulin
action has been confirmed in functional studies in which simu-
ltaneous substitution of all three residues with nonphosphorylat-
able alanines prevented insulin-inhibition of IGFBP-1-Luc reporter
activity in transfected HEK-293 cells (Fig. 3e). When examined
individually, the single substitution mutants (Ser98 R Ala, Ser101
R Ala, Ser102 R Ala) also repressed insulin inactivation of
IGFBP-1-Luc (Fig. 3e), indicating that the phosphorylation of
Ser98, Ser101 and Ser102 are each indispensable for insulin
activity. Differences in the magnitude of Luc activity in HEK-293
cells transfected with single-substitution mutants suggest that trans-
activationbyHMGA1 is dependent on both the number and position
of phosphate groups on the HMGA1 C-terminaltail. Thisisconsistent
with our previous finding which showed that phosphorylation of the
multiple serine residues at the HMGA C-terminus is not a random
event, as the phosphorylation of a serine residue can influence
phosphorylation at an adiacent site
9. Also, these results confirm the
current view on the role of the acidic C-terminal tail phosphorylation
in the negative modulation of HMGA DNA-binding properties and
thus in their transactivation ability
9,20. No hyperphosphorylation of
HMGA1a, besides that occurring at the C-terminal tail, was de-
tected after insulin treatment. On the contrary, a slight decrease in
the phosphorylation status of some peptides (aa 1–6, 7–14, 18–22, 30–
54, and 71–73) was detected (Supplementary Fig. S4 and Supple-
mentary Table S1). Some of them contain serine/threonine residues
near the HMGA1 DNA-binding domains, supporting the notion that
decreased HMGA1a DNA-binding affinity after insulin treatment
is dependent on phosphorylation of the acidic C-terminal tail of
HMGA1 (Supplementary Data).
The effect of insulin-induced phosphorylation on nuclear dis-
tribution of HMGA1 was then investigated in living cells. Analysis
with the green fluorescent protein (GFP)-tagged HMGA1a (GFP-
HMGA1a) revealed that, in serum-starved HepG2 cells, the GFP-
HMGA1a fusion protein was preferentially located within the tran-
scriptionally active euchromatin in the nuclear interior (Fig. 3f).
After 15 min of insulin treatment there was a marked redistribution
ofGFP-HMGA1afromthissitetotherepressedinactiveheterochro-
matin,inacircumferentialdistributionwithinthenucleus,becoming
moreevident at 30 min(Fig. 3f).Pretreatment with the PI-3K inhib-
itor wortmannin totally reversed insulin-induced heterochromatin
foci formation and resulted in a more diffuse and homogenous
distribution of GFP-HMGA1a throughout the entire nucleus simi-
larly to that in starved control cells (Fig. 3f). To verify the specifi-
city of insulin-induced phosphorylation on nuclear localization
of HMGA1, we examined the nuclear distribution of the mutant
GFP-HMGA1am (mimicking dephosphorylation), in which the
three active serine phosphorylation sites at the C-terminus were
mutated to nonphosphorylatable alanines. As shown in Fig. 3f,
insulin elicited no effect on this mutant, confirming that phosphor-
ylation at these sites was essential for regulating HMGA1 activity by
insulin. Mobility analysis by photoactivation confirmed that, in
serum-starved HepG2 cells, the photoactivable GFP protein
(PAGFP)-tagged HMGA1a (PAGFP-HMGA1a) was preferentially
located in the nuclear interior (Supplementary Video S1). Once
again, insulin treatment caused a marked redistribution of
PAGFP-HMGA1a from the nuclear interior site to the peripheral
region of the nucleus, and this effect was reversed by wortmannin
and was prevented in cells expressing the mutant PAGFP-
HMGA1am protein (Supplementary Video S1). Thus, these results
indicatethatinsulinismechanisticallyinvolvedinthedynamicinter-
action of HMGA1 with DNA/chromatin in vivo.
Insulin-induced INSR downregulation is mediated by HMGA1
phosphorylation. Downregulation of INSR mRNA by insulin has
been demonstrated in vitro with several cell types
22. Indeed, we
previously showed that mRNA for the INSR was upregulated in
insulin-starved mammalian cells
23,24, in which this rise was
paralleled closely by a rise in a small nuclear protein (later found
to be HMGA1)
11,24. In the present work, to probe further the
relevance of HMGA1 for the INSR signaling system, we carried
out studies in cultured HepG2 cells as well as in mice,
demonstrating that phosphorylation of HMGA1 is an essential and
necessary prerequisite for the insulin-induced INSR downregulation
either invitro or in vivo.Asshown in Fig. 4a,HepG2 cells upregulate
the INSR mRNA in the absence of serum, conditions that induce the
dephosphorylation and activation of HMGA1; conversely, insulin
was able to reverse this effect. Inhibition of INSR expression by
insulin was abolished in HepG2 cells almost completely depleted
of HMGA1 (Fig. 4a). Consistently with our model, inhibition of
INSR mRNA by insulin in HepG2 cells paralleled closely the
decrease in HMGA1 occupancy at the endogenous INSR locus
(Fig. 4a). In concert with these observations, INSR mRNA abund-
ance was increased in liver from 12 h-fasted normal mice (Fig. 4b,c)
and was reduced in mice with augmented insulin levels as obtained
following either systemic administration of insulin (Fig. 4b), or after
meal ingestion (Fig. 4c). As with IGFBP-1 gene, binding of
endogenous HMGA1 to the INSR gene locus was increased in liver
from mice under physiological fasting conditions, when the insulin
signaling cascade is attenuated (Fig. 4b,c), and promptly decreased
following insulin injection (Fig. 4b) or after refeeding (Fig. 4c), when
insulin signaling is reactivated, indicating that HMGA1 acts as a
molecular switch for activating or deactivating INSR expression
during the fasting and refeeding periods, respectively. In line
with this, insulin failed to suppress INSR mRNA in the absence
of HMGA1, as observed in primary cultured hepatocytes from
HMGA1-null mice (Fig. 4d), and no changes on INSR mRNA
levels were observed in insulin-treated HEK-293 cells overex-
pressing single (HMGA1am-Ser) or triple (HMGA1am) HMGA1
protein mutants (Fig. 4d).
Thus, these data collectively underscore the importance of the
architectural factor HMGA1 in the context of the INSR signaling
pathway, and establish HMGA1 as a novel key player in the nutri-
tionally and insulin-regulated transcription of genes involved in glu-
cose metabolism.
Discussion
The intracellular signaling pathways by which changes in gene
expression are triggered by insulin are only partly identified and
more investigations are needed to decipher the molecular mechan-
ismsofthistranscriptionalregulation.Theinitialinteractionofinsu-
lin with target cells is via its receptor located in the plasma
membrane
25–27.Upon bindingof insulin, theINSR undergoes autop-
hosphorylation which enables the receptor to have a kinase activity
and phosphorylates various cytoplasmic INSR substrates (IRSs).
From this point, signaling proceeds via a variety of signaling path-
ways (i.e. PI-3K signaling pathway, Ras and MAP kinase cascade)
that are responsible for the metabolic, growth-promoting and mito-
genic effects of insulin. Based on these considerations, it is possible,
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 251 | DOI: 10.1038/srep00251 6Figure 4 | Insulin-induced INSR downregulation is mediated by HMGA1 phosphorylation. (a) Left, serum-starved HepG2 cells, either untreated or
pretreated with HMGA1-siRNA, were incubated without or with insulin (10 nM) for 12 h. Total RNA was extracted, and mRNA for the INSR was
quantitatedbyqRT-PCR.RPS9 mRNAwasusedtonormalize.Datarepresentmean6s.e.m.ofthreeindependentexperiments;*P,0.05versusinsulin/
siRNA-untreatedcells.RepresentativeWBofHMGA1proteinexpressionisshownintheautoradiogram.b-actin,controlofproteinloading.Right,ChIP
shows that binding ofHMGA1 tothe INSRgene promoter (INSR-E3) was decreased in serum-starved HepG2 cells treated with insulin. Arepresentative
assay out of three independent experiments is shown. Right side, ChIP with a non-AT-rich sequence in the INSR locus. qRT-PCR of ChIP-ed samples is
shownineach condition. *P,0.05versusinsulin/siRNA-untreated sample (slashedbar).(b)12 h-fasted wild-type micewere intraperitoneally injected
witheither insulin (1 U/kgbw) or saline and sacrificed 2–4 hlater. Left, total RNA wasisolated from liver, INSR mRNA was measured by qRT-PCR and
normalized to RPS9 mRNA abundance. Results are the mean values 6 s.e.m. from six animals per group. *P , 0.05 versus untreated (saline) control
mice.Right,occupancyoftheINSR-E3genepromoterbyHMGA1asmeasuredbyChIPwithanti-HMGA1specificantibody(Ab)inliverfrommiceafter
treatment with saline or insulin. A representative assay is presented. qRT-PCR of ChIP-ed samples is shown in each condition. *P , 0.05 versus insulin-
untreated sample (slashed bar). (c) Left, liver INSR mRNA was assayed as in (b) in 12 h-fasted mice (n 5 6), and mice refed for 4 h (n 5 5) with a high
carbohydrate diet after a 12-h fast. *P , 0.05 versus fasted mice. Right, phosphorylation change affecting the interaction of HMGA1 with the INSR-E3
genepromoterduringthefast/fedtransitionisshownbyChIPinvivo,onwholeliver.qRT-PCRofChIP-edsamplesisshownineachcondition.*P,0.05
versus fasted sample (slashed bar). (d) Insulin-mediated INSR mRNA downregulation in primary cultured hepatocytes from wild-type (1/1) and
Hmga1-null (2/2) mice (left), and in HEK-293 cells overexpressing either wild-type (HMGA1a), triple (HMGA1am) or single (HMGA1am-Ser)
HMGA1a mutants (right). INSR mRNA levels were measured by qRT-PCR in cells untreated or treated with 10 nM insulin for 12 h. In each condition,
data are shown as the means 6 s.e.m. of five independent experiments. *P , 0.05 versus untreated (1/1) cells; **P , 0.05 versus insulin untreated
(HMGA1a) control. Protein expression of HMGA1 in primary hepatocytes and HEK-293 cells is shown by WB. b-actin, control.
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glucose metabolism may result, at least in part, from posttransla-
tional modifications, including phosphorylation, that can affect
access of transcription factors to DNA, thereby silencing and/or
unsilencing gene expression. This possibility, that would account
for the pleiotropic effects of this hormone, is greatly supported by
our current findings here, indicating that, by inducing HMGA1 pro-
teinphosphorylation,insulinisdirectlyandmechanisticallyinvolved
inthedynamicinteractionofHMGA1withDNA/chromatininvivo,
thus in the control of gene activity.
Here we provide evidence that HMGA1 plays an essential role in
thetranscriptionalregulationofavarietyofinsulin-targetgenessuch
as IGFBP-1 and INSR genes, as well as the gluconeogenic genes
PEPCK and G6Pase. IGFBP-1 is distinctive among the IGFBPs, as
its plasma concentrations show marked diurnal variations due to
hormonal and metabolic changes. IGFBP-1 is thought to be the
primary IGF binding protein involved in the acute regulation of
serum glucose levels
28. Fasting hyperglycemia with impaired glucose
tolerance and insulin resistance has been demonstrated in rats after
the injection of IGFBP-1
28, as well as in transgenic mice overexpres-
sing IGFBP-1
29, in the presence of reduced concentrations of cir-
culating free IGF-I. Given that IGFBP-1 serum levels were
considerably decreased in Hmga1-knockout mice
17 and IGFBP-1
mRNA expression was also reduced in HepG2 cells by siRNA tar-
geting HMGA1, it appears reasonable to interpret that insulin-
induced functional inactivation of HMGA1, by adversely affecting
the production of IGFBP-1 protein species, could serve as a mech-
anism to increase the insulin-like effects of endogenous IGF-I,
thereby contributing to the maintenance of postprandial glucose
homeostasis. The contribution of HMGA1 to the postprandial regu-
lation of glucose homeostasis is supported by our observations in
primary cultured hepatocytes, indicating that repression of the glu-
coneogenic genes PEPCK and G6Pase by insulin requires HMGA1.
Consistent with these observations, we previously found that
the counter-regulatory hormone glucagon, which acts in opposition
to insulin to maintain a euglycemic (normal) state, upregulates
HMGA1 protein production in vivo in whole mice
30. Based on our
findings here, it is likely that upregulation of HMGA1 during fasting
(when glucagon peaks) may also contribute to the maintenance of
fasting euglycemia. In addition, the hypothesis that HMGA1, by
increasing fastingserumIGFBP-1, maycontributetorestrictglucose
uptake by peripheral tissues, thereby sparing glucose for the brain
and other glucose-dependent tissues, is also supported.
The molecular mechanisms regulating INSR gene expression have
been elucidated and evidence has been provided showing that
HMGA1 is required for proper transcription of the INSR gene in
mammals
11,12. HMGA1 acts on the INSR gene promoter as an ele-
ment necessary for the formation of a transcriptionally active multi-
protein-DNAcomplexinvolving,inadditiontotheHMGA1protein,
theubiquitouslyexpressedtranscriptionfactorSp1andtheCCAAT-
enhancer binding protein beta (C/EBPb)
12. By potentiating the
recruitment and binding of Sp1 and C/EBPb to the INSR promoter,
HMGA1 greatly enhances the transcriptional activities of these fac-
torsin thecontext ofthe INSR gene
12.Asdemonstrated inthis study,
consistently with the observation that functional repressionof endo-
genous HMGA1 is strictly dependent on insulin-induced HMGA1
phosphorylation, INSR gene expression was considerably reduced in
vitro,ininsulin-treatedHepG2cells,andinvivo,inliverfromnormal
mice with augmented insulin levels as obtained following insulin
injection or after a meal.
The possibility that intracellular regulatory molecules that are
employed by the INSR signaling system could be involved in post-
translationalmodificationsofHMGA1,includingproteinphosphor-
ylation, has been postulated before, on the basis of experimental
observations in vitro, involving the novel PKCe isotype that has
recently been shown to be linked to the insulin signaling pathway
31.
The literature, however, does not provide explanation on how these
modificationsoccurandfunctioninconcert.Herein,weprovidedata
that help explain these issues and add new insights into the physio-
logical mechanistic details governing INSR signal transduction. In
view of our results on the HMGA1 post-translational modifications,
it appears likely that variations in the biological activity of HMGA1
canbespecificallyproducedinresponsetohormonalandnutritional
changes through mechanisms of phosphorylation/dephosphoryla-
tionoftheHMGA1 protein,leading togenerepression oractivation,
respectively. These findings may not only play a role under physio-
logical circumstances related to acute metabolic and hormonal res-
ponses (e.g., after a meal, or when insulin decreases during fasting),
butmayalsocontributetopathophysiologicalpathwaysinarangeof
blood sugar-related disorders, in which insulin levels are chronically
elevated. In this regard, data have been published indicating that
type 2 diabetes mellitus may occur in humans and mice carrying
HMGA1 gene defects, in which abnormalities of both the insulin-
receptorsignaling systemandtheIGF-I–IGFBP-1 systemwereiden-
tified
17,32,33.
The FOXO (forkhead) family of transcription factors are critical
regulators of insulin action, and cytoplasm retention of FOXOs via
phosphorylationissuggestedtobeamechanismofinsulin-mediated
IGFBP-1andINSR gene repression
34–36.The possibility thataninter-
play among HMGA1 and FOXO can be a component of this regu-
lation constitutes an interesting point that will deserve further
consideration.Comparedtopreviousinvestigations,forthefirsttime
in the present study, we report the identification of HMGA1 as a
novel downstream nuclear target of the INSR signaling pathway,
which may play a major role in insulin-dependent gene expression
and regulation in mammals. This, in our opinion, is interesting from
bothbiologicalandmechanisticpointsofviewandmightbeusefulin
understanding the molecular basis of clinical phenotypes in certain
conditions where insulin action becomes compromised (i.e. diabetes
mellitus, obesity and other insulin-resistant syndromes). Under-
standing these mechanisms should augment our capacity to identify
novel therapeutic targets for the prevention and treatment of these
diseases.
Methods
Plasmidconstructionandtransfections,nucleardistributionandphotoactivation
analysis and qRT-PCR. Primers used for plasmid construction of human IGFBP-1
promoter-containing vector: 59-TAGCCCCTGAGCTCTGCCTAG-39 (containing
SacIrestrictionsite)and59-ACAGGGGCCGAAGCTTTCTGG-39(containingHind
III restriction site). PCR products were subcloned into pGL3-basic vector (Promega)
at the indicated restriction sites. Recombinant Luc reporter construct in the presence
or absence of effector vector for HMGA1 (HMGA1a isoform protein)
12, were
transiently transfected into HepG2 cells, using LipofectAMINE 2000 reagent
(Invitrogen), and Luc activity was assayed 48 h later in a luminometer (Turner
Biosystems), using the dual-luciferase reporter assay system (Promega). siRNA
targeted to human HMGA1
37, plus nonspecific siRNA controls with a similar GC
content were obtained from Dharmacon. 100–200 pmol siRNA duplex was
transfected into cells at 40% to 50% confluency. After knockdown for 72 h, the cells
were trypsinized, pooled, and resuspended for a second transfection using the same
targeting siRNA. After an additional 72 h, cells were prepared for analysis. Renilla
control vector served as an internal control of transfection efficiency, together with
measurements of protein expression levels. Site-directed mutagenesis of the serine
phosphorylation sites of HMGA1a was carried out by using the site-directed
mutagenesis kit (Stratagene) with the following pair of PCR primers (59-
AAGAGGAGGGCATCGCGCAGGAGGCCGCGGAGGAGGAGCAG-39 and 59-
CTGCTCCTCCTCCGCGGCCTCCTGCGCGATGCCCTCCTCTT-39, sites for
mutagenesis are underlined) to yield single and triple HMGA1a mutants.
To produce GFP-HMGA1a and PAGFP-HMGA1a expression plasmids, the
humanHMGA1aORF(NCBIRef.Seq.NM_145899.2)wasclonedintoBamHI/XbaI
sites of pGFP (Clontech) or PAGFP expression vector (a kind gift from Dr. Faretta,
European Institute of Oncology, Milan, Italy), respectively. HepG2 cells were trans-
fected with either wild-type or mutant GFP-HMGA1a or PAGFP-HMGA1a effector
plasmid, spotted the day after on glass bottom poly-D-lysine coated plates (Met-Tek
Corporation), and used for time-lapse imaging or photoactivation studies, respect-
ively. For time-lapse studies, images were collected on a Leica TCS-SP2 confocal
microscope (Leica Mycrosystems) with a 63x Apo PLA oil immersion objective (NA
1.4) and 60-mm aperture. GFP-expressing cells were visualized by excitation with an
argon laser at 488 nm and photomultiplier tube voltage of 420 mV. For photoacti-
vation studies, transfected cells were first identified by scanning for low levels of
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wasperformed on selected cells following cell activation by a 200 msec 406 nm pulse
at 100% laser power focused to a spot of approximately 1.5 mm diameter. A series of
single Z-sections of each cell was recorded over 1 min after photoactivation using a
FITC filter.
For qRT-PCR, total cellular RNA was extracted from cells and tissue using the
RNAqueous-4PCRkitandsubjectedtoDNasetreatment(Ambion).RNAlevelswere
normalizedagainst18SribosomalRNAineachsample,andcDNAsweresynthesized
from 2 mg of total RNA using the RETROscript first strand synthesis kit (Ambion).
Primers for mouse IGFBP-1 (NM_008341) (59-CCTAACTGTTGTTTCTTGGC-39;
59-AGAAATCTCGGGGCACGAA-39), human IGFBP-1 (NM_000596.2) (59-
CATTCCATCCTTTGGGAC-39;5 9-ATTCTTGTTGCAGTTTGGCAG-39), human
INSR (NM_000208.2) (59-TTTGGGAAATCACCAGCTTGGCAGAAC-39;5 9-
AAAGCTGGGGTGCAGGTC GTCCTTG-39), mouse INSR (NM_010568) (59-
TATGACGACTCGGCCAGTGA-39;5 9-ATCTGGAAGTGTGAGTGTGG-39),
mouse PEPCK1 (NM_011044) (59-GTGTCATCCGCAAGCTGAAGA-39;5 9-
CTTTCGATCCTGGCCACATCT-39), mouse G6Pase (NM_008061) (59-
CTGCCAGGGAGAACTCAGCAA-39;5 9-GAGGACCAAGGAAGCCACAAT-39)
were designed according to sequences from the GenBank database. A real-time
thermocycler (Eppendorf Mastercycler ep realplex ES) was used to perform quant-
itativePCR.Ina20-mlfinalvolume,0.5mlofthecDNAsolutionwasmixedwithSYBR
Green RealMasterMix (Eppendorf), and 0.3 mM each of sense and antisense primers.
The mixture was used as a template for the amplification by the following protocol: a
denaturing step at95uCfor 2 min, then anamplification and quantification program
repeated for 45 cycles of 95uC for 15 s, 55uC for 25 s, and 68uC for 25 s, followed by
the melting curve step. SYBR Green fluorescence was measured, and relative quan-
tification was made against RPS9 cDNA used as an internal standard. All PCR
reactions were done in triplicates.
Animals.Allanimalworkwasconductedaccordingtoinstitutionalguidelinesforthe
care of laboratory animals. For the wortmannin studies, wild-type mice were given
single bolus injections of wortmannin (1 mg/kg bw) or vehicle (0.5% DMSO) alone
via the tail vein, followed 1 h later by an intraperitoneal injection of insulin (1 U/kg
bw). The liver was harvested 4 h after insulin injection to determine Akt
phosphorylation and HMGA1-DNA binding, in addition to IGFBP-1 expression.
INSR mRNA and ChIP of the INSR promoter gene were analysed in liver from 12 h-
fasted mice after intraperitoneal injection of insulin (1 U/kg bw) or saline and after
4 h refeeding. Mouse hepatocytes were isolated as described elsewhere
38. Primary
hepatocytes were cultured on matrigel-coated six-well plates in Williams E media
(Sigma) supplemented with 10% FBS. 1.522.5310
6 cells were allowed to adhere for
2–3 h and were then incubated in serum-free DMEM containing 0.1% BSA. Cells
were maintained in this medium overnight (12 h) and then utilized in subsequent
experiments.
ChIP. ChIP assay was performed in cultured HepG2 cells, either untreated or
pretreated with HMGA1 siRNA as described previously
17,39. For in vivo ChIP, at the
endof the indicated treatments, mice were killed by cervical dislocation, the liver was
rapidly removed, prewarmed with PBS, and treated with collagenase (0.2%) for
15 min. The liver was then diced, forced through a 60 mm stainless steel sieve, the
hepatocyteswerecollecteddirectlyintoDMEMcontaining1%formaldehyde,andthe
formaldehyde-fixed DNA-protein complexes were immunoprecipitated with anti-
HMGA1 antibody
17,39. Sequence-specific primers for IGFBP-1 and INSR gene
promotersusedforPCRamplificationofChIPDNA(30cycles),usingPCRready-to-
go beads (Amersham Pharmacia Biotech): human IGFBP-1 (NT_007819) for 59-
CAGAAAGAGAAGCAATTCCG-39, rev 59-TACCAGCCAGACGCGAGCAA-39;
mouse IGFBP-1 (NT_039515) for 59-CCTGGGGAGGGAGAAACAACT-39,r e v5 9-
GCAGTGTTCAATGCTCGCTGG-39; human INSR (NT_11255.14) for 59-
AGATCTGGCCATTGCACTC-39, rev 59-ATGCCAGTTCTGGGGAGGTA-39;
mouse INSR (NC_000074.5) for 59-TTGTTGGGCGCCTACTAGC-39, rev 59-
AAACACAAGTAACACCGAGG-39. Primers for ChIP with non-AT-rich
sequences: human IGFBP-1 locus [for 59-AGTAGAGATGGGGTTTTGCC-39
(22266/22247fromtheATG),rev59-GATAGCAATGCCTTCTTGTG-39(22022/
22003fromtheATG)];humanINSRlocus[for59-TCCCCTGCAAGCTTTCCCTC-
39 (2586/2567 from the ATG), rev 59-TACTGAGCGGAGGCCCTTGCGGT-39
(2226/2204 from the ATG). PCR products were electrophoretically resolved on
1.5% agarose gel and visualized by ethidium bromide staining. Primers for qRT-PCR
ChIP-ed samples are available upon request.
IP/WB. These assays were performed to analyse IGFBP-1 protein expression in
HepG2 cells and in whole-cell liver extracts (1 mg) from treated and untreated mice,
using a polyclonal specific antibody raised against IGFBP-1 (Santa Cruz
Biotechnology). For the measurement of IRS-1 and Akt phosphorylation, protein
extracts(1 mg)frommicewerepreparedandanalysedaspreviouslydescribed
17.IRS-
1tyrosinephosphorylationwasassayedafterIPoftotallysateswithantibodytoIRS-1,
followed by immunoblotting with anti-phosphotyrosine antibody. WBs for Akt were
performed using antibody that recognizes only phosphorylated Ser473 form of Akt
and antibody that recognizes total (nonphosphorylated and phosphorylated) Akt in
liver. The antibodies used for these studies were: anti-phosphotyrosine, anti-IRS-1,
anti-Akt, anti-pAkt (Upstate Biotechnology). A polyclonal-specific antibody against
HMGA1
11 was used to analyse HMGA1 protein expression in HepG2 cells.
EMSA. Nuclear extracts were prepared from liver of wild-type animals, injected or
not with insulin, and binding of HMGA1 to DNA was assessed using a
32P-labeled
oligonucleotide duplex corresponding to the human INSR E3 promoter element
11,24.
In supershift assays nuclear protein was preincubated with 1 mg polyclonal antibody
to HMGA1 before addition of the probe.
HMGAproteinextraction,HPLC,LC-MSandLC-MS/MSanalyses.HMGproteins
from HepG2 cells were selectively extracted by treating cells with 5% perchloric acid
(PCA), precipitated by acetone-HCl, resuspended in water and their presence
confirmed by SDS-PAGE
9. By employing these conditions, endogenous HMG
proteins were also extracted from the whole liver of wild-type mice intraperitoneally
injected with insulin (1 U/kg bw) or saline after 12 h fasting. Reverse-phase HPLC
chromatography and LC-MS analyses were carried out using a PerkinElmer Life
Sciences apparatus (Series 200 LC Pump), using a RP Supelco Discovery BIO Wide
Pore C5 column (2.13250 mm, 5 mm) directly interfaced with an ESI interface to an
ion trap HCTultra mass spectrometer (Bruker Daltonics). HPLC separations were
carried out using a water/acetonitrile gradient with 0.05% TFA as a modifier. MS
parameters were the following: full MS scan: m/z 600–1100; mass range mode:
standard/enhanced; ion charge control (ICC) active allowing the storage of a
maximum of 200000 ions in a maximum accumulation time of 200 msec. LC-MS
were elaborated with Data Analysis software (version 3.4, Bruker Daltonics).
Identities of proteins were obtained by comparison of theoretical with experimental
molecular masses, taking into consideration combinations of the various post-
translational modifications. LC-MS/MS analyses were performed as previously
described
9andwereusedtomapthephosphorylationincreaseinHMGA1asequence.
HMGA1a protein was extracted from control and insulin treated HepG2 cells and
purified (HPLC). Equal amounts of HMGA1a were then trypsin digested and LC-
MS/MS analysed. Among all the peptides found, the phosphorylated counterparts
were searched.
Statistics. Statistical significance was evaluated using a 2-tailed Student’s t test. P ,
0.05 was considered significant. All bar graph data shown represent mean 6 s.e.m.
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